Skip to main content
All lobbying filings

FRESENIUS KABI USA LLC

Lobbying for FRESENIUS KABI USA LLC

 Filing 1st Quarter - Report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted May 6, 2025
Expenses
$712,941.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Illinois

Official filing document

 Lobbyists on this filing 3
  • SARAH CHRISTINE D'ORSIE
    Previously held: Congressman Tom Davis
  • TIMOTHY CASEY
    Previously held: Congressman John Tierney Senator Tom Carper
  • STEVEN CHASE WALKER New on this filing
    Previously held: Congressman Jodey Arrington

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 10
  • Centers For Medicare and Medicaid Services (CMS)
  • Commerce, Dept of (DOC)
  • Executive Office of the President (EOP)
  • Food & Drug Administration (FDA)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • Patent & Trademark Office (PTO)
  • SENATE
  • U.S. Trade Representative (USTR)
  • White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Lobbying activity 7
Manufacturing

Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launch

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, made in America

Pharmacy

PBM reform, including spread pricing, AWP policy, ASP policy

Medicare/Medicaid

PBM reform, patent reform, ASP reform, international reference pricing, IRA Medicare negotiation, inflation penalty

Taxation/Internal Revenue Code

BEAT, AMT, U.S. manufacturing incentives

Health Issues

Drug pricing, PBM Reform, patent reform, biosimilars, generics, medical devices, FDA approvals, DEHP

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem